Five Prime Therapeutics Inc. (NASDAQ:FPRX)’s share price was down 5.7% during mid-day trading on Wednesday . The company traded as low as $45.61 and last traded at $45.73, with a volume of 211,543 shares trading hands. The stock had previously closed at $48.51.

A number of equities analysts have issued reports on FPRX shares. Jefferies Group set a $60.00 price objective on shares of Five Prime Therapeutics and gave the company a “buy” rating in a research report on Friday, August 5th. Leerink Swann restated a “buy” rating and issued a $45.00 price objective on shares of Five Prime Therapeutics in a research report on Friday, July 15th. Credit Suisse Group AG restated a “buy” rating on shares of Five Prime Therapeutics in a research report on Tuesday, July 12th. Finally, Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $48.00 price objective on shares of Five Prime Therapeutics in a research report on Thursday, May 19th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $52.33.

The company has a market cap of $1.20 billion and a PE ratio of 5.02. The firm’s 50 day moving average price is $47.05 and its 200 day moving average price is $41.82.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.07. The business had revenue of $9.23 million for the quarter, compared to the consensus estimate of $6.38 million. Five Prime Therapeutics’s revenue for the quarter was up 46.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.45) EPS. On average, equities research analysts forecast that Five Prime Therapeutics Inc. will post ($2.37) earnings per share for the current fiscal year.

In other Five Prime Therapeutics news, Director William R. Ringo sold 500 shares of the stock in a transaction on Monday, August 1st. The shares were sold at an average price of $50.77, for a total transaction of $25,385.00. Following the completion of the transaction, the director now owns 500 shares in the company, valued at $25,385. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Peder Jensen sold 12,195 shares of the stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $49.50, for a total transaction of $603,652.50. Following the transaction, the director now owns 12,195 shares of the company’s stock, valued at approximately $603,652.50. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Five Prime Therapeutics stock. RS Investment Management Co. LLC acquired a new stake in shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 511,170 shares of the company’s stock, valued at approximately $21,214,000. RS Investment Management Co. LLC owned approximately 1.86% of Five Prime Therapeutics at the end of the most recent quarter.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.